Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550679 | 1.00 | ALOX15 (0.50) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL29245226 | 0.89 | TYMS (0.43) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL2087097 | 0.80 | TDP1 (0.60) | ALOX15TDP1TYMSTSHRALDH1A1 | |
| SCHEMBL31548711 | 0.80 | TDP1 (0.60) | ALOX15TDP1TYMSTSHRALDH1A1 | |
| SCHEMBL4959191 | 0.78 | PARP1 (0.42) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL29688935 | 0.78 | TSHR (0.52) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL855646 | 0.78 | TSHR (0.52) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL23966517 | 0.77 | ALDH1A1 (0.40) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL322393 | 0.77 | TYMS (0.62) | ALOX15TDP1CA1CA2CA7 | |
| SCHEMBL29937612 | 0.77 | TYMS (0.62) | ALOX15TDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120152967-A | Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119798197-A | Method for preparing halogenated phthalic anhydride by micro-interface enhanced catalytic oxidation | 哈尔滨工业大学（威海） | 2025-04-11 | — | — | CN | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119630651-A | Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025010326-A2 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-112638380-B | Cerebellar protein (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-110240629-B | Protein degradation targeting BCR-ABL compound and antitumor application thereof | 上海科技大学 | 2023-10-03 | — | — | CN | disclosed |
| US-20230099634-A1 | STYRENE-BASED RESIN COMPOSITION, FLAME RETARDANT STYRENE-BASED RESIN COMPOSITION, MOLDED BODY, AND PATCH ANTENNA | PS JAPAN CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114286678-A | Compounds for inhibiting and inducing degradation of EGFR and ALK | 北京泰德制药股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | ALOX15 471/4885TDP1 3731/4885CA1 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.